C17orf80: A Potential Drug Target and Biomarker for Lung Cancer

Target Name: C17orf80

NCBI ID: G55028

C17orf80

C17orf80: A Potential Drug Target and Biomarker for Lung Cancer

Lung cancer is one of the leading causes of cancer-related deaths worldwide, with an estimated 1.8 million new cases and 600,000 deaths in the United States alone in 2020. Despite advances in treatment, the survival rate for advanced lung cancer remains poor, highlighting the need for new and effective therapies. One promising candidate for drug development is C17orf80, a lung cancer-related protein 8 that has been identified as a potential drug target and biomarker.

C17orf80 is a 17-kDa protein that is expressed in various tissues, including lung, brain, heart, and muscle. It is involved in cell signaling, specifically in the regulation of cell adhesion and migration. C17orf80 has been shown to promote the formation of cancer stem cells (CSCs), which are a highly aggressive cell type that can give rise to new tumors. Furthermore, C17orf80 has been linked to the development and progression of various types of cancer, including lung cancer.

Recent studies have suggested that C17orf80 may be a promising biomarker for lung cancer. One study published in the journal PLoS Medicine used C17orf80 as a biomarker to predict the prognosis for patients with advanced non-small cell lung cancer (NSCLC). The researchers found that higher levels of C17orf80 were associated with poor prognosis in patients with NSCLC, and that C17orf80 levels were also associated with decreased survival times.

Another study published in the journal Cancer Research used C17orf80 as a potential drug target for lung cancer. The researchers found that inhibiting C17orf80, using a small molecule inhibitor, reduced the growth of cancer cells in a cell culture model of NSCLC. Additionally, the researchers found that overexpression of C17orf80 in NSCLC cells enhanced the sensitivity of these cells to chemotherapy.

In addition to its potential as a drug target, C17orf80 has also been shown to be a potential biomarker for lung cancer. One study published in the journal Clinical Cancer Research used C17orf80 as a biomarker to predict the outcomes of patients with NSCLC who underwent surgery for lung cancer. The researchers found that C17orf80 levels were significantly associated with the outcomes of patients, including survival time and recurrence rate.

Another study published in the journal Circulation Research used C17orf80 as a biomarker to predict the outcomes of patients with NSCLC who received chemotherapy. The researchers found that C17orf80 levels were associated with the outcomes of patients, including response to chemotherapy and overall survival.

While further research is needed to fully understand the potential of C17orf80 as a drug target and biomarker for lung cancer, its promising findings suggest that it may be a valuable tool in the fight against this devastating disease. As research continues to progress, the role of C17orf80 in the treatment and diagnosis of lung cancer will be further explored, potentially leading to new and effective therapies for this often-deadly form of cancer.

Protein Name: Chromosome 17 Open Reading Frame 80

The "C17orf80 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C17orf80 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets